Menu

Recent Interviews

Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)

info@cleanlogistics.de

+49-4171-6791300

Interview Clean Logistics: Hydrogen challenge to Daimler + Co.


Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


03. November 2019 | 07:37 CET

BAYER, MERCK OR NOVARTIS - WHO BUYS NOXXON PHARMA?

  • Pharma
Photo credits: pixabay.com

The therapy and cure of serious diseases is a large market with a high willingness to invest. Companies that are active in research and development need experienced teams and partners as well as a lot of liquidity and opportunities to carry out tests. Bayer, Merck and Novartis are well-known global players in the research and treatment of cancer. It is not uncommon for these companies to work with small partners and, if successful, to even acquire them. A transaction may be imminent.

time to read: 1 minutes by Mario Hose
ISIN:


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


FURTHER STUDIES ACCORDING TO NEW DATA

The Berlin-based biotech company NOXXON focuses on the treatment of pancreatic and colorectal cancer as well as brain tumors. Based on the published, updated data from the clinical NOX-A12 study in metastatic, microsatellite-stable patients with pancreatic or colorectal cancer in September 2019, NOXXON believes that further clinical studies in these indications are justified.

The development can be described as a successful development. In the next step, the company aims to find industry partners to provide anti-PD1 therapy and financial support to conduct a study.

SIGNIFICANT ADVANCES IN NOX-A12

"The near final data from the NOX-A12 study in combination with immunotherapy in patients with metastatic, microsatellite-stable pancreatic or colorectal cancer and the start of another NOX-A12 study in combination with radiotherapy in the first-line treatment of brain tumor patients are significant advances in the clinical development of NOX-A12 for NOXXON. We are still in discussions with potential partners to enter into agreements to share the financial risks associated with the further development of our cancer therapies," said Aram Mangasarian, Chief Executive Officer of NOXXON.

PHASE 1/2 STUDY HAS STARTED

NOXXON has started the phase 1/2 study with NOX-A12 in combination with radiotherapy. According to the company, patients with inoperable brain tumors (glioblastoma) for whom biomarker analysis confirms that they do not benefit from standard chemotherapy will be treated.

If the data from this study show positive results, the company will discuss the most efficient development path for this indication with the relevant authorities in a Scientific Advice, taking into account orphan drug status in the US and Europe.

ACQUISITION CAN OFFER TIME ADVANTAGE

NOXXON's goal is to identify industry partners for the combination of NOX-A12 with radiotherapy to fund further clinical trials in brain tumors and other indications where radiotherapy is the key component of standard therapy.

NOXXON expects that at least preliminary top-line clinical data from this study will be required to enter into a partnership in this area. The advantage of acquiring NOXXON for a major player is that it will gain a head start in a market worth billions. The coming weeks will be exciting.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

04. August 2021 | 11:10 CET | by André Will-Laudien

XPhyto Therapeutics - Groundbreaking diagnostic platforms of the future

  • Biotechnology
  • Pharma

The number of infectious diseases that we humans are fighting today has increased significantly in recent decades, not just because they have become known and researched. Increasingly frequent variants and neoplasms have also led in turn to entirely new disease patterns. An important area upstream of the medical sector is the large diagnostics market. The umbrella term of diagnostics is used in particular in the context of the detection and differentiation of diseases. This is referred to as clinical diagnostics. Many test and diagnostic procedures are assigned to the bioscience sector since studies must first prove their exact validity. Worldwide, more than 10,000 companies are involved in symptom research, the detection, screening and analysis of the diagnosis of diseases.

Read

14. July 2021 | 10:54 CET | by Armin Schulz

Cardiol Therapeutics, CureVac, Bayer - Where is the journey heading?

  • Pharma

One might think that the pharmaceutical industry is the big winner of the Corona Crisis. However, according to a study by EY, this is not the case. Sales did increase by an average of 4.4% at the largest pharma companies, a much better result than in many other industries, but compared to 2019, growth actually fell by 8.4%. That is due to the postponement of medical treatments due to the Corona Crisis. The industry benefits from the ever-increasing number of elderly people worldwide and, at the same time, the development of new drugs. As a result, sales and profits have increased even during the crisis. We, therefore, highlight three companies from the pharma sector.

Read

02. March 2021 | 11:15 CET | by André Will-Laudien

Q&M Dental, Pfizer, BioNTech, Teva: Watch out for these pharma picks!

  • Pharma

The COVID pandemic has permanent surprises in store, which strongly influence our daily life. The province of Tyrol was sealed off entirely 2 weeks ago. The Czech Republic is being helped out with vaccine doses because the incidence figures are going through the roof. In Germany, hairdressers and DIY stores have been allowed to open again. Gradually, everyday life is returning to normal, but it will probably take some time before we regain the quality of life of the pre-Corona years. Let's take a closer look at various business models in the healthcare industry to get a feel for what's next.

Read